Creo Medical Group (CREO)

Sector:

Health Care

Index:

FTSE AIM All-Share

34.25p
   
  • Change Today:
    -0.50p
  • 52 Week High: 48.10
  • 52 Week Low: 23.25
  • Currency: UK Pounds
  • Shares Issued: 361.48m
  • Volume: 709,100
  • Market Cap: £123.81m

Creo Medical signs IP licence deal with CMR Surgical

By Josh White

Date: Monday 24 Oct 2022

LONDON (ShareCast) - (Sharecast News) - Surgical endoscopy device company Creo Medical Group has signed a non-exclusive intellectual property licence and a royalty agreement with surgical robotics business CMR Surgical, it announced on Monday, to integrate certain aspects of Creo's technology with the 'Versius' surgical robotic system through its 'powered by Kamaptive' licensing programme.
The AIM-traded firm said licensing terms and commercial royalties had been agreed, but would remain undisclosed.

It said CMR's next-generation surgical robot, Versius, was a "significant" new entrant into the robotic surgery space, and was being used to perform both routine and complex laparoscopic procedures across a range of specialties including gynaecology, colorectal surgery, thoracic surgery, general surgery and urology.

Through Creo's Kamaptive licensing programme, strategic partners were being selected for Creo to licence and develop its technology for use in "adjacent and complementary" markets.

"We are delighted to announce our second robotics partnership through our Kamaptive programme with CMR Surgical," said chief executive officer Craig Gulliford.

"Versius has been used for a wide range of laparoscopic procedures worldwide, and we look forward to collaborating with CMR to integrate Creo's ground-breaking minimally invasive technology with the Versius system, driven by a shared goal to improve outcomes for even more patients.

"Exploring the use of our technology in the fast-growing robotic surgery space with another prestigious partner provides further validation of our technology and its versatility."

At 1400 BST, shares in Creo Medical were up 2.68% at 49.8p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

CREO Market Data

Currency UK Pounds
Share Price 34.25p
Change Today -0.50p
% Change -1.44 %
52 Week High 48.10
52 Week Low 23.25
Volume 709,100
Shares Issued 361.48m
Market Cap £123.81m

CREO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
20.42% below the market average20.42% below the market average20.42% below the market average20.42% below the market average20.42% below the market average
40% below the sector average40% below the sector average40% below the sector average40% below the sector average40% below the sector average
Price Trend
24.69% above the market average24.69% above the market average24.69% above the market average24.69% above the market average24.69% above the market average
51.35% above the sector average51.35% above the sector average51.35% above the sector average51.35% above the sector average51.35% above the sector average
Income Not Available
Growth
40.14% above the market average40.14% above the market average40.14% above the market average40.14% above the market average40.14% above the market average
66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average

What The Brokers Say

Strong Buy 2
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CREO Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
17:08 36,389 @ 34.25p
16:30 15,000 @ 34.38p
16:29 580 @ 34.45p
16:10 29,500 @ 34.50p
16:03 236,617 @ 33.51p

CREO Key Personnel

CEO Craig Jonathan Gulliford
CFO Richard John Rees

Top of Page